Gastroesophageal reflux disease is a progressive disease

Digestive and Liver Disease

Volumn 39, Issue 5, 2007, Pages 409-414

  Pace, F ^a   Pallotta, S ^a   Vakil, N ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c MARQUETTE UNIVERSITY   (United States)

Author keywords

Erosive oesophagitis; GERD natural history; NERD

Indexed keywords

ESOMEPRAZOLE; PROTEIN P16; PROTEIN P53; PROTON PUMP INHIBITOR;

ARTICLE; BARRETT ESOPHAGUS; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HUMAN; PATHOPHYSIOLOGY; STOMACH ACID SECRETION;

ANIMALS; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 33947715908     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.11.015     Document Type: Article

References (37)

1. Cantù P., Savojardo D., Carmagnola S., and Penagini R. Impact on referral for gastro-oesophageal reflux disease on the workload of an academic Gastroenterology Unit. Dig Liver Dis 37 (2005) 735-740
2. Stanghellini V., Cogliandro R., Cogliandro L., De Giorgio R., Barbara G., and Corinaldesi R. Unsolved problems in the management of patients with gastroesophageal reflux disease. Dig Liver Dis 35 (2003) 843-848
3. Howard P.J., and Heading R.C. Epidemiology of gastro-oesophageal reflux disease. World J Surg 16 (1992) 288-293
4. El-Serag H.B., and Sonnenberg A. Associations between different forms of gastro-oesophageal reflux disease. Gut 41 (1997) 594-599
5. Locke III G.R., Talley N.J., Fett S.L., Zinsmeister A.R., and Melton III L.J. Prevalence and clinical spectrum of gastro-oesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112 (1997) 1448-1456
6. Wong W.M., Lai K.C., Lam S.K., Hui W.M., Hu H.C., Lam C.L.K., et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 18 (2003) 595-664
7. Pace F., and Bianchi Porro G. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol 99 (2004) 946-949
8. Fass R., and Ofman J.J. Gastroesophageal reflux disease: should we adopt a new conceptual framework?. Am J Gastroenterol 97 (2002) 1901-1909
9. Labenz J., Jaspersen D., Kulig M., Leodolter A., Lind T., Meyer-Sabelelk W., et al. Risk factor for erosive esopahgitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 99 (2004) 1652-1656
10. Quigley E.M.M. Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease. Am J Gastroenterol 98 Suppl. (2003) S25-S30
11. Tack J., and Fass R. Approaches to endoscopy-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder?. Aliment Pharmacol Ther 19 Suppl. 1 (2004) 28-34
12. Malfertheiner P., Lind T., Willich S., Vieth M., Jaspersen D., Labenz J., et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 54 (2005) 746-751
13. Fass R. Distinct phenotypic presentations of gastroesophageal reflux disease: a new view on natural history. Dig Dis 22 (2004) 100-107
14. DeVault K.R., and Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 190-200
15. Pace F., Manes G., Conio M., and Bianchi Porro G. Pretreatment endoscopy-Pro & Contra: endoscopy is needed before treatment in all patients with gastroesophageal reflux disease. Endoscopy 38 (2006) 271-275
16. Pace F., Santalucia F., and Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut 32 (1991) 845-848
17. Pace F., Bollani S., Molteni P., and Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD)-a reappraisal 10 years on. Dig Liver Dis 36 (2004) 111-115
18. Schindlbeck N.E., Klauser A.G., Berghammer G., Londong W., and Mueller-Lissner S.A. Three years follow up of patients with gastroesophageal reflux. Gut 33 (1992) 1016-1019
19. Isolauri J., Luostarinen M., Isolauri E., Reinikainen P., Viljakka M., and Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 years follow-up of 60 patients. Am J Gastroenterol 92 (1997) 37-41
20. McDougall N.I., Johnston B.T., Kee F., Collins J.S.A., McFarland R.J., and Love A.H.G. Three to 4.5 year prospective study of prognostic indicators in gastrooesophageal reflux disease. Scand J Gastroenterol 33 (1998) 1016-1022
21. Pace F., Pallotta S., Molteni P., Zentilin P., Russo L., Savarino V., et al. Natural history of NERD in 3 Italian tertiary referral centres after 5 years of follow-up. Gut 55 Suppl. V (2006) A62
22. Bayerdorffer E., Sipponen P., Bigard M., Weiss W., Mearin F., Rodrigo L., et al. Esomeprazole 20 mg continuous vs. on demand treatment of patients with endoscopy-negative reflux disease (ENRD). Gut 53 Suppl. 6 (2004) A106
23. Labenz J., Nocon M., Lind T., Leodolter A., Jaspersen D., Meyer-Sabellek W., et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 101 (2006) 2457-2462
24. Kawanishi M. Will symptomatic gastroesophageal reflux disease develop into reflux esophagitis?. J Gastroenterol 41 (2006) 440-443
25. Fullard M., Kang J.Y., Neild P., Poullis A., and Maxwell J.D. Systematic review: does gastro-oesophageal reflux disease progress?. Aliment Pharmacol Ther 24 (2006) 33-45
26. Manabe N., Yoshihara M., Sasaki A., Tanaka S., Haruma K., and Chayama K. Clinical characteristics and natural history of patients with low-grade esophagitis. J Gastroenterol Hepatol 17 (2002) 949-954
27. Ollyo J.B., Monnier P., Fontolliet C., and Savary M. The natural history, prevalence and incidence of reflux oesophagitis. Gullet 3 Suppl. (1993) 3-10
28. Cameron A.J., and Lomboy C.T. Barrett's esophagus: age, prevalence and extent of columnar epithelium. Gastroenterology 103 (1992) 1241-1245
29. Bajbouj M., Reichenberger J., and Neu B. A prospective multicenter clinical and endoscopic follow-up study of patients with gastroesophageal reflux disease. Z Gastroenterol 43 (2005) 1303-1307
30. Lagergren J., Bergstrom R., Lindgren A., and Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
31. Chow W.H., Finkle W.D., McLaughlin J.K., Frankl H., Ziel H.K., and Fraumeni Jr. J.F. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the oesophagus and gastric cardia. JAMA 274 (1995) 474-477
32. Farrow D.C., Vaughan T.L., Sweeney C., Gammon M.D., Chow W.H., Risch H.A., et al. Gastroesophageal reflux disease, use of H2 receptor antagonists and risk of esophageal and gastric cancer. Cancer Causes Control 11 (2000) 231-238
33. Conio M., Cameron A.J., Romero Y., Branch C.D., Schleck C.D., Burgart L.J., et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 48 (2001) 304-309
34. Reid B.J., Barrett M.T., Galipeau P.C., Sanchez C.A., Neshat K., Cowan D.S., et al. Barrett's esopahgus: ordering the events that lead to cancer. Eur J Cancer Prev 5 Suppl. 2 (1996) 57-65
35. Jankowski J.A., Harrison R.F., Perry I., Balkwill F., and Tselepis C. Barrett's metaplasia. Lancet 356 (2000) 2079-2085
36. Correa P., Haenszel W., Cuello C., Tannenbaum S., and Archer M. A model for gastric cancer epidemiology. Lancet 2 (1975) 58-60
37. Sontag S., Sonneneberg A., Schnell T.G., Leya J., and Metz A. The long-term natural history of gastroesopahgeal reflux disease. J Clin Gastroenterol 40 (2006) 398-404